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The upper airway is generally defined as the air passage segment that extends between the naso-
or oropharynx and the carina. The longest segment of the upper airwaydthe tracheadbegins at
the inferior portion of the larynx and extends to the branch point of themain carina. The trachea
has the potential to be a “forgotten zone” in differential diagnoses, as pathological processes
involving this portion may not receive prominent clinical consideration in disorders presenting
with respiratory symptoms and signs. Unlike the oropharynx, this anatomical area is beyond visu-
alization on routine inspection; unlike the mediastinum and lung fields, it is a potential “blind
spot” on initial, plain radiographic examination of the chest. Nonetheless, the adult trachea
is affected by a number of primary disorders and is also a target organ of a variety of systemic
diseases. This review will focus on both primary and systemic diseases involving the adult tra-
chea with specific attention to their clinical manifestations and diagnostic hallmarks.
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The upper airway extends between the naso- or oropharynx
and the carina. The longest segment of the upper air-
waydthe tracheadbegins at the inferior portion of the
larynx and extends to the branch point of the main carina, a
length of 10e16 cm. Its inner diameter is 21e27 mm and is
supported anteriorly and laterally by 15e20 C-shaped,
cartilaginous rings that protect the integrity of the airway1
(Fig. 1, panel A). It lies anterior to the esophagus; the non-
reinforced, posterior wall of the trachea is appropriately
compressible during swallowing. The trachea has the po-
tential to be a “forgotten zone” in differential diagnoses,
as pathological processes may not receive prominent clin-
ical consideration as other more common disorders pre-
senting with similar respiratory symptoms.2 Unlike the
oropharynx, this anatomical area is beyond visualization onroutine inspection; unlike the mediastinum and lung fields,
it is a potential “blind spot” on the routine, plain radio-
graphic examination of the chest.3 Nonetheless, the adult
trachea is affected by a number of primary disorders and is
also a target organ of a variety of systemic diseases. If this
anatomic area is not considered in the differential diagnosis
the results can be disastrous because unlike the lower air-
ways, the upper airway has no collateral ventilation and
airflow obstruction can be life threatening. This review will
focus on primary and systemic diseases involving the adult
trachea. Specific attention will be paid to their clinical
manifestations and diagnostic hallmarks.
Physiology of airflow in the upper airway
The shape and function of the larynx and trachea are of
great importance from a physiologic and clinical point of
Figure 1 Panel A: Anatomy of upper airway (adapted from
Surgery of the Trachea and Bronchi, by H. Grillo. Copyright
2004, PMPH-USA. Reprinted with permission) panel B: virtual
bronchoscopy using CT scan reconstruction shows appearance
of tracheal rings and intact mucosa.
The “forgotten zone” 1303view. Depending on the density of gas molecules, flow rate,
and airway diameter; the pattern of airflow may be laminar
or turbulent.4,5 Laminar flow usually occurs in the very
small airways where flow is reduced. In the larynx andtrachea where air velocity is high, airflow is usually turbu-
lent. The driving pressure for turbulent flow is proportional
to the square of the flow rate and inversely related to the
fifth power of the radius. Thus, a minor decrease in the
radius of the upper airway results in a significant increase in
the driving pressure necessary to achieve the same airflow.
The inhalation of a low-density gas such as helium-oxygen
mixture has been successfully used with acute upper
airway obstruction as it increases the proportion of laminar
flow.6 This decreases the density-dependent driving pres-
sure required for airflow.
Classification of tracheal disorders
Tracheal disorders result from intrinsic disorders (in-
fections, inflammatory disorders, trauma, and malignancy)
or extrinsic compression from adjacent structures (Table
1). These disorders manifest mainly as obstruction of the
upper airway (narrowing or stenosis). However, when the
integrity of tracheal wall is lost, tracheal dilatation (tra-
cheomegaly) may develop and can be associated with
tracheal scalloping or diverticulosis. Such deformities may
predispose the trachea to dynamic collapse during inspira-
tion or expiration in extrathoracic and intrathoracic central
airway involvement respectively.
Clinical manifestations
The clinical manifestations of tracheal disorders are deter-
mined by the extent and location of the abnormalities.
Tracheal obstruction can be life-threatening acutely as, un-
like the lower airways, it has no collateral ventilation. Acute
obstruction is a life-threatening condition and typically pre-
sents with inspiratory stridor that is best heard in the neck,
and with cough, and dyspnea. Most primary and systemic
diseases involving the adult trachea are more insidious. Pa-
tients with extrathoracic stenosis may have hoarseness,
inspiratory wheezing, stridor, and nonproductive cough.
However, intrathoracic stenosis may cause more difficulty
with expiration and worsening dyspnea in the recumbent po-
sition. In addition, patients with normal cardiopulmonary
reserve may present with dyspnea only on exertion. In gen-
eral, dyspnea at rest develops when the upper airway diam-
eter isdecreasedby75% (<5mm).Thepresenceofpreexisting
pulmonary disease may result in significant dyspnea at lesser
degrees of airway narrowing. Furthermore, tracheobronchial
stenosis may impair clearance of secretions and increase the
risk of respiratory infections. Patients with tracheal disorders
may have dyspnea and wheezing that mimic asthma but with
no response to bronchodilators.
Intrinsic disorders
Infections
Diffuse swelling of the larynx and trachea associated with
signs of upper airway obstruction is not uncommon in chil-
dren in the setting of certain acute upper respiratory viral
diseases, such as those caused by parainfluenza types 1e3,
the most common causes of the croup syndrome; influenza A
and B viruses; adenoviruses; coronavirus NL63; and
Table 1 Classification of tracheal disorders.
A) Intrinsic
1. Infectious
Viral
Bacterial
Fungal
2. Inflammatory/Infiltrative
Relapsing polychondritis
Granulomatosis with polyangiitis (Wegener’s
granulomatosis)
Sarcoidosis
Amyloidosis
Rheumatoid arthritis
Miscellaneous: inflammatory bowel diseases
3. Non-inflammatory
Tracheomalacia (and Mounier-Kuhn syndrome,
Saber-Sheath deformity)
Excessive dynamic airway collapse
Tracheopathia osteochondroplastica
Idiopathic tracheal stenosis
4. Iatrogenic
Post-intubation tracheal stenosis
5. Neoplastic
Primary neoplasm (squamous carcinoma,
adenoid cystic carcinoma)
Secondary neoplasm (metastasis)
B) Extrinsic
Extrinsic compression (lymph node, carcinoma,
vascular anomalies)
Extrinsic diseases infiltrating the trachea
Fibrosing mediastinitis
Mediastinal granuloma
Tracheobroncholithiasis
1304 M.O. Al-Qadi et al.respiratory syncytial virus.7 In adults, such clinical mani-
festations are less likely because of their cumulative
immunologic experience with environmental respiratory vi-
ruses and the relatively large diameter of the adult trachea.
However, several, severe, viral-associated acute infections
of the upper airways are described in adults. Tracheal
involvement, manifested as focal or diffuse necrotizing
tracheitis was frequently observed in autopsy analyses of 34
decedents from the 2009 H1N1 influenza A outbreak in New
York City8; concurrent lower respiratory tract involvement
was also nearly universally identified in this study.8,9
A variety of pathogens have been described as etiologic
agents of acute or chronic upper airway diseases in adults
(Table 2). Nearly all reported cases are associated with
epidemiologic predispositions in the host. Risks include
immunocompromised states, local damage to the tracheal
mucosa from a variety of sources, and upper airway
involvement with systemic infections. For some infectious
diseases, only isolated case reports are available; others
are more commonly associated with diseases of the upper
airways in adults.
Tracheal papillomatosis is a benign condition caused by
human papilloma virus (most commonly HPV-6 and HPV-11)
characterized by papillomatous growth of the laryngeo-
tracheal epithelium. The disease is more common in early
childhood before the age of 5 years and affects male morethan female.31 The larynx is involved in most cases and is
rarely limited to the trachea. Longstanding laryngotracheal
papillomatosis may transform to squamous cell carcinoma.
Invasive Aspergillus tracheobronchitis is an uncommon
but well described syndrome that generally has been re-
ported in the same profoundly immunocompromised pa-
tient populations at risk for disseminated aspergillosis.32 It
has been described with several different species of
Aspergillus. With less severe infection mucosal inflamma-
tion or intraluminal obstruction may occur, the latter due
to exuberant growth of exophytic fungal collections. Both
generally occur in settings of local tracheal injury, such as
prolonged endotracheal intubation or previous nonfungal
infection.33 Aspergillus tracheobronchitis may also cause
more severe disease with pseudomembranous and ulcera-
tive lesions, generally in more profoundly immunocompro-
mised individuals.33 The prognosis associated with severe
disease is typically poor, in large part related to the un-
derlying severity of immune suppression in the host. Ul-
cerative disease tends to have a slightly better outcome, as
it is usually associated with limited involvement of the
respiratory tree. Many cases have occurred in the setting of
organ transplantation. They are more likely to be diagnosed
early and thus respond to early antifungal therapy.34
Pseudomembranous invasive Aspergillus tracheobronchitis
typically affects individuals with profound immunosup-
pressed states and is nearly universally fatal.34
Laryngeotracheal histoplasmosis is extremely rare and
typically associated with disseminated disease in immuno-
compromised patients. In immunocompetent individuals,
primary infections are asymptomatic or present as a flu-like
illness. The disease is endemic in the river valleys in the
central United States. Mucosal lesions begin as painless flat
plaques. Later, these lesions ulcerate and may resemble
squamous cell carcinoma.35 Histoplasmosis may cause
external compression of central airways due to granulo-
matous lesions or calcified massive mediastinal lymph
nodes, which may erode into adjacent airways.
Rhinoscleroma is a slowly progressive granulomatous
disease caused by Klebsiella rhinoscleromatis. This gram-
negative bacterium is endemic in tropical and subtropical
areas.36 The disease typically involves the nose, paranasal
sinuses, and central airways; and progresses slowly over
years. Granulomatous nodules may cause partial obstruc-
tion of the involved airways and may progress to fibrosis
with stenosis in later stages. Treatment consists of pro-
longed antibiotic therapy.
Nosocomial tracheobronchitis occurs in 1e3% of in-
dividuals in ICUs.37,38 One study found 201 cases over a 6.5-
year period in non-immunocompromised, critically ill in-
dividuals intubated for more than 48 h; gram-negative or-
ganisms, most commonly Pseudomonas aeruginosa, account
for 75% of isolates.37 This entity, also known as ventilator-
associated tracheobronchitis (VAT), has been associated
with increased duration of mechanical ventilation and
length of stays in the ICU.37,38 VAT is probably part of a
continuum between respiratory tract microbial colonization
and ventilator-associated pneumonia (VAP); nearly one-third
of VAT patients progressed to VAP in one study.38 Antimi-
crobials appear to lower ICU-associated mortality in VAT.39
Tuberculosis tracheitis is a rare clinical manifestation of
tuberculosis that is considered one of the most
Table 2 Infectious etiologies of acute tracheitis in adults.
Microbial etiology Epidemiology Tracheal lesions Refs
Herpes simplex virus Immunocompromised host; prolonged
intubation; corticosteroids; AIDS
Necrotic ulcerations with squamous
metaplasia; reversible cause of
tracheal stenosis
10e13
Corynebacterium
pseudodiphtheriticum
Mucosal damage from antecedent
viral URI; endotracheal intubation
Necrotizing tracheitis 14
Aspergillus spp. AIDS; acute or chronic leukemias
associated with neutropenia; solid
organ transplantation (lung, kidney,
heart); tracheal injury due to
chronic infection
Necrotizing tracheobronchitis with
ulcers, pseudomembranes, hyphae;
mycetoma formation; no fungal
invasion of lungs; transmural extension
with possible bronchoarterial fistula
15e21
Candida albicans Prolonged endotracheal intubation,
tracheostomy
Intraluminal fibrinoid membrane
comprising fungal elements
22
Pasteurella multocida CLL, anti-TNF monoclonal antibody
treatment
Symptoms and sputum culture only;
no bronchoscopy
23
Microsporidiosis AIDS Tracheal involvement as part of
disseminated infection; squamous
metaplasia; parasites in macrophages
and in lamina propria
24
CMV AIDS Necrotizing tracheitis 24
Mycobacterium
tuberculosis
Diffuse tracheal stenosis; usually
associated with pulmonary disease
Klebsiella
rhinoscleromatis
Rhinoscleroma affects nose and paranasal
sinuses but may affect nasopharynx, larynx,
trachea. Chronic, progressive,
granulomatous infection endemic in Africa,
South America,
and other parts of the developing world.
Rare in developed world.
Diffuse tracheal stenosis 25
Staphylococcus
aureus
Antecedent tracheal mucosal injury Acute membranous tracheitis
Pseudomonas
aeruginosa
Prolonged mechanical ventilation,
tracheostomy
Not described 26
Bacillus cereus Aplastic anemia, antilymphocyte globulin Pseudomembranous tracheobronchitis 27
Aeromonas veronii Near-drowning Non-occlusive tracheobronchitis 28
Actinomycosis Congenital tracheal bronchus Not described 29
Sporothrix schenckii Cirrhosis, tracheal involvement as part
of extracutaneous sporotrichosis
Yeast forms in tracheal tissue 30
The “forgotten zone” 1305communicable forms of the disease due to the high burden
of mycobacteria expelled by coughing.40 It typically results
from contiguous spread from peribronchial lymphatics or
mediastinal lymph nodes. Sequelae include obstruction due
to mucosal necrosis and edema and secondary fibrosis and
airflow obstruction upon healing. Chronic tuberculosis may
also cause fibrosing mediastinitis, associated with secondary
involvement of the trachea and central airways through
contiguous encroachment by the mediastinal infection.
However, this clinical presentation is more commonly
observed in relation to chronic histoplasmosis (see below).41
Inflammatory and infiltrative disorders
Relapsing polychondritis
Relapsing polychondritis is a rare episodic and progressive
multisystem inflammatory disease of the proteoglycan-rich
structures. The exact etiology of the disease remains un-
known. However, the presence of fibrocartilagenous infil-
tration with CD4þ lymphocytes, immune deposits in tissuelesions, and elevated levels of autoantibodies against type
II collagen suggest an immunologic mechanism.42 Patients
with relapsing polychondritis may have an associated con-
nective tissue disease, systemic vasculitis, myelodysplastic
syndrome, or lymphoproliferative disorder. The disease
primarily affects cartilages of external ears, larynx and
tracheobronchial tree, sparing the posterior membranous
part of the trachea. The disease occurs in all age groups and
affects males and females equally. Upper airway compli-
cations develop in up to 55% of patients and may include
subglottic stenosis, tracheal wall thickening with subse-
quent stenosis, and tracheobronchomalacia.43 Large airway
disease can be subtle in the early stages of the disease.
Respiratory symptoms such as cough, wheezing, hoarse-
ness, stridor and dyspnea are present in up to 50% of pa-
tients.44 These symptoms should be taken seriously as the
severity of symptoms poorly correlates with the extent of
the disease and may herald life-threatening collapse of
central airway. Dynamic CT may reveal expiratory collapse
of central airways.45
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granulomatosis)
Wegener’s represents a small-vessel vasculitis character-
ized by necrotizing granulomatous inflammation that
mainly involves the upper airway, lungs and the kidneys. It
has a peak incidence in the fourth and fifth decades of life.
Most patients have upper airway involvement and the tra-
chea (typically the subglottic area) is affected in 10e20% of
patients. Although the disease affects males and females
equally, more than 90% of patients with tracheal stenosis
are females.46 Subglottic stenosis is more frequent in pa-
tients with early age of onset.47 Patients usually present
with symptoms such as hoarseness, sore throat, stridor,
cough, hemoptysis, or dyspnea. Bronchoscopy may reveal
laryngeal stenosis, focal subglottic eccentric or concentric
tracheal stenosis, tracheal ulceration, calcification of
tracheal rings, and inflammatory pseudo-polyps. Trans-
bronchial lung biopsy can be used to confirm the diagnosis
and may be evident for vasculitis, necrosis, or granuloma-
tous inflammation. Approximately half of patients who
have bronchoscopic abnormalities demonstrate histopath-
ologic features consistent with the disease.48 However, the
full spectrum of histologic features on individual biopsy is
only present in 16% of specimens. Approximately, ninety
percent of patients have elevated anti-neutrophilic cyto-
plasmic antibodies (c-ANCA).49
Sarcoidosis
A multisystemic granulomatous disease of unclear etiology,
the disease is characterized by activation of CD4þ T-lym-
phocytes and macrophages that leads to the formation of
epithelioid non-caseating granulomas in the affected or-
gans. Sarcoidosis usually affects individuals in the 25- to 50-
year-old age group. Although the respiratory system is
involved in more than 90% of patients, central airway
involvement is uncommon and is often overlooked.50 The
trachea and main bronchi can be affected by intrinsic
granulomatous infiltration or by extrinsic compression of
enlarged mediastinal and hilar lymph nodes. The upper part
of the trachea is affected in 1%e3% of patients, while distal
trachea and lower airways are less frequently involved.
Patients with upper airway involvement may be asymp-
tomatic or may present with unexplained cough, dyspnea,
or wheezing. These symptoms are more related to airway
hyperresponsiveness due to tracheal mucosal involvement
rather than mechanical obstruction.51 Airway involvement
in sarcoidosis is also associated with increased morbidity
and mortality.
Amyloidosis
Amyloidosis is caused by deposition of abnormal hetroge-
nous fibrillary misfolded proteins that form from immuno-
globulins produced by clonal plasma cells. Systemic
amyloidosis may result in functional upper airway
dysfunction because of macroglossia. Tracheobronchial
amyloidosis is the commonest pulmonary pattern seen in
patients with primary (AL) amyloidosis and is more common
in males.52 The disease has predilection to the larynx and
can result in laryngeal stenosis.53 Patients may have
tracheal diffuse multifocal plaques within the sub-mucosa
and is usually associated with poor prognosis. Tumor-like
“amyloidomas” may be seen in localized amyloidosisconfined to the tracheobronchial tree and is usually more
benign although it may result in mechanical obstruction.
These endoscopic abnormalities are sometimes confused
with other intrinsic tracheobronchial disorders, especially
tracheopathia osteochondroplastica.
Rheumatoid arthritis
Rheumatoid arthritis is an autoimmune disease character-
ized by chronic symmetric inflammatory arthritis, with
various extraarticular manifestations. The disease is char-
acterized by tissue infiltration with T lymphocytes and
plasma cells, hyperplasia and hypertrophy of synovial lining
cells. The laryngeal structures are involved in 26%e53% of
patients.54,55 Patients may have arthritis of the cricoar-
ytenoid joint, rheumatoid nodules of the vocal cords, and
vocal cords paralysis secondary to ischemic atrophy of the
recurrent laryngeal nerves. The most common symptoms
are hoarseness, sore throat and fullness, and dyspnea. In
addition, isolated tracheal involvement has been reported
and usually presents with of cough. Chest radiographs and
pulmonary function studies are usually necessary to
exclude the presence of parenchymal lung disease.
Inflammatory bowel diseases
Tracheobronchial manifestations of inflammatory bowel
diseases are uncommon. These include ulcerative trache-
itis, bronchiectasis, and obliterative bronchiolitis.56
Tracheobronchial involvement is more common with ul-
cerative colitis than Crohn’s disease and rarely precedes
the intestinal manifestations.57 Concentric ulceration,
calcification of the tracheal cartilages, and irregular
luminal narrowing may be evident by bronchoscopy.58 His-
topathologic examination may reveal submucosal fibrosis
with chronic inflammation. Patients may present with stri-
dor, dyspnea, and dry cough.Non-inflammatory
Tracheomalacia (TM)
TM is a weakness of the tracheal wall due to loss of the
cartilage integrity. This can be localized to a tracheal
segment or diffuse extending to one or both main bronchi
(ie. tracheobronchomalacia). TM can be classified accord-
ing to the morphologic appearance of the trachea. The
anterioposterior wall narrowing is called “crescent type” or
“scabbard shape” and lateral wall narrowing is referred to
as “saber-sheath type”.59
TM predisposes the trachea to dynamic collapse during
expiration (intrathoracic trachea) or inspiration (extra-
thoracic trachea) with 10e20% narrowing of the tracheal
lumen.60 TM can be idiopathic with significant tracheal
dilatation (tracheomegaly) as in “Mounier-Kuhn syndrome”
and the diagnosis is usually established when the diameter
of the trachea, right main bronchus and left main bronchus
exceed 3.0, 2.4, and 2.3 cm respectively on standard
radiograph.61 Mounier-Kuhn syndrome can be associated
with tracheal scalloping or diverticulosis. Secondary TM can
result from damage to tracheal wall from external
compression, pressure and ischemia of the internal tracheal
wall (eg. post-intubation), or chronic inflammation of the
bronchi (chronic bronchitis) or tracheal cartilages (eg.
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segmental and typically <3.0 cm in length. TM may present
with nonspecific symptoms like dyspnea, cough or hemop-
tysis often attributed to a coexisting pulmonary disease
such as chronic bronchitis. In addition, patients may
develop recurrent infections and bronchiectasis due to poor
clearance of secretions.62 Dynamic tracheal collapse visu-
alized by bronchoscopy is considered the gold standard for
the diagnosis of tracheomalacia.63 The presence of an
anterior bulging posterior tracheal wall, narrowed ante-
roposterior tracheal luminal diameter, and widened pos-
terior membranous tracheal wall is very suggestive of TM.
“Saber-Sheath” deformity is a rare deformity of the
intrathoracic trachea characterized by marked decrease in
the transverse diameter of the trachea associated with an
increase in its sagittal diameter. Saber-sheath trachea de-
velops almost exclusively in men with chronic obstructive
pulmonary disease (COPD) with a specificity of 92.9%.65 This
deformity results from mechanical forces of hyperinflated
lungs that cause narrowing of the coronal diameter of the
intrathoracic trachea and elongation of the sagittal diam-
eter with abrupt widening of the tracheal lumen above the
thoracic inlet. The diagnosis is made when the coronal to
the sagittal diameter (measured 1 cm above the aortic
arch) is equal to or less than 0.5 as this condition is not
thought to cause symptoms.66
Excessive dynamic airway collapse (EDAC)
Excessive dynamic airway collapse represents collapse of
the posterior membranous tracheal wall with 50% or more
reduction of the sagittal diameter during expiration or
coughing.64 In contrast to tracheomalacia, EDAC is not
related to a structural or functional cartilage pathology.
However, tracheomalacia and EDAC may coexist.
Tracheobronchopathia osteochondroplastica (TPO)
A rare disorder characterized by the presence of sub-
mucosal cartilaginous nodules and ossified lesions. The
disease affects the cartilaginous part of the trachea and
spares the posterior membranous wall.67,68 These lesions
usually form a semicircular endotracheal structure that
may vary in shape. It is usually diagnosed in individuals
older than 50 and is slightly more common in males.
Although TPO was thought to be a form of primary localized
amyloidosis with ossification, the exact etiology remains
unknown. Some studies have shown possible association
between TPO and atrophic rhinitis.69 Bone morphogenetic
protein 2 (BMP-2) may have a role in the pathogenesis of
TPO.70 The disease typically affects the lower two thirds of
the trachea and proximal bronchi. Patients can be asymp-
tomatic or may present with cough, dyspnea, hemoptysis,
and recurrent pneumonia. Chest radiographs may show
calcified tracheal wall and/or narrowing of the tracheal
lumen. Nodular irregularity of the anterior and lateral walls
seen at bronchoscopy and punctate calcification evident on
the CT scan can be diagnostic.71
Idiopathic laryngotracheal stenosis
A rare condition characterized by stenosis at the level of
the cricoid cartilage and upper trachea with no apparent
clinical or pathologic etiology. Most patients are diagnosed
in their fourth and fifth decade of life. The disease hasstrong female predominance suggesting a possible hor-
monal role in the pathogenesis. Some studies of estrogen
receptors (ER) and progesterone receptors (PR) have shown
positive staining of fibroblasts in most cases.72 However,
the clinical significance of this is unclear. Several patho-
logic mechanisms have been postulated with a possible role
of gastroesophageal reflux disease (GERD).73 A study of
ambulatory 24-h pH monitoring in patients with idiopathic
tracheal stenosis showed significant pharyngeal acid reflux
compared to the control group.74
Iatrogenic
Post-intubation tracheal stenosis
Ischemic injury of tracheal mucosa may complicate trauma
and several therapeutic interventions such as endotracheal
intubation, tracheostomy, and radiation therapy.75 The
incidence of post-intubation tracheal stenosis (PITS) is
estimated up to 21% and is more common in females. PITS
can present as concentric web-like membranous stenosis
without cartilage damage. Furthermore, “A” shaped ste-
nosis that resembles the vocal cords may result when the
lateral tracheal wall is damaged, hence called pseudo-
glottic stenosis. A more extensive “complex” stenosis with
circumferential hourglass-like contraction can also develop
when the tracheal cartilage is damaged. High-pressure cuff
in addition to low capillary pressure (eg. hypotension)
result in tracheal mucosal ischemia and chondritis with
subsequent fibrosis anywhere from the site of cuff down to
the distal end of the tube. The stoma of the tracheostomy
is another potential site for stenosis in patients with
tracheostomy.
Neoplastic
Tracheal tumors represent only 2% of all upper airway tu-
mors.76 In adults, tracheal tumors are most commonly
malignant and occur between the third and fifth decades of
life.77 These tumors commonly arise from the distal third of
the trachea. Squamous cell carcinoma and adenoid cystic
carcinoma account for up to 85% of all malignant adult
tracheal tumors.78 Secondary tracheal tumors are usually
caused by direct invasion from the lung, thyroid, or
esophagus. Metastasis to the trachea is rare but may be
seen in breast, gastrointestinal, or renal cell carcinoma.79
Extrinsic disorders
External compression
The trachea can be compressed extrinsically by benign and
malignant tumors of the surrounding structures (eg. thy-
roid, esophagus) as well as adjacent lymph nodes and
vascular structures. Distinct pathologies that may cause
external compression are reviewed here.
Fibrosing (sclerosing) mediastinitis
A rare disorder that results from exaggerated granuloma-
tous inflammatory response to different pathogens. The
disease is characterized by excessive proliferation of
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vessels, esophagus, trachea, and bronchi). 50%e70% of
cases are related to Histoplasma capsulatum. Leakage of
fungal antigens from lymph nodes into the mediastinal
space leads to a hypersensitivity reaction that progress
slowly over months to years. Cases attributable to Myco-
bacterium tuberculosis and fungi such as Coccidioides
immitis, Aspergillus flavus, in addition to methylsergide
have been also reported. Airways are involved in approxi-
mately 20% of cases with tracheal narrowing or compression
in 15%e30% of cases. Chest radiographs usually reveal
widened mediastinum due to massive adenopathy and
fibrosis.
Tracheobroncholithiasis
Tracheobroncholithiasis is caused by erosion of calcified
peribronchial lymph node into the tracheobronchial tree.80
It usually complicates granulomatous lymphadenitis caused
by mycobacterial or fungal infections. Patients typically
present with cough and expectoration of fragments of
calcified material. The identification of a calcified lymph
node on chest CT and presence of calcified material in
combination with acute inflammation or granulation tissue
on histopathology are suggestive of the diagnosis.
Diagnostic evaluation
When tracheal disorder is suspected, securing an airway
should start simultaneously with the diagnostic workup.
Evaluation of the trachea involves several non-invasive
imaging and physiologic modalities. These studies are
complementary to more invasive procedures such as
bronchoscopy.
Radiographic assessment
The aim of imaging is to localize the pathology, describe
the nature of the disease (diffuse or focal, intrinsic or
extrinsic), and if present determine if the obstruction is
dynamic or fixed. Plain AP and lateral soft tissue radio-
graphs of the neck can be helpful in diagnosing acute
extrathoracic upper airway obstruction. However, the tra-
chea and central airways are best evaluated by computed
tomography (CT). With the recent advances in imaging,
more sensitive modalities such as multi-detector computed
tomography (MDCT) and magnetic resonance imaging (MRI)
have replaced conventional imaging modalities.81 MDCT
provides high-resolution images that can be used to
generate multiplanar reformations, 3D volume-rendered
images, and virtual bronchoscopic images.
Chest roentgenogram and lateral films of the neck
Evaluation of the larynx and extrathoracic trachea is
composed of anteroposterior (AP) and lateral films of the
neck and oblique views of the trachea with the head
slightly hyperextended. This lateral view provides useful
information about diseases that involve the sagittal plane,
including the anterior and posterior tracheal wall.82 The
intrathoracic trachea can be visualized on routine chest
radiograph. However, abnormalities may be obscured by
overlying mediastinal and bony structures.Fluoroscopy of the trachea
Fluoroscopy of the trachea is used to assess the compliance
of tracheal wall.83 In addition, weakness of the tracheal
wall can be visualized during breathing. Extrathoracic
tracheal weakness results in bulging (eg. laryngocele or
pharyngocele) during the Valsalva maneuver. However,
during forced inspiration, collapse may occur as the
pressure around the extrathoracic trachea exceeds the
intratracheal pressure. In contrast, weakness of the intra-
thoracic trachea (eg. tracheobronchomalacia) results in
expiratory collapse.
Computed tomography (CT)
CT scan has become the modality of choice in the evalua-
tion of upper airway disease. Helical CT scanning (HCT)
provides imaging of the whole thorax during a single breath
hold. This technique minimizes artifacts due to respiratory
motion and allows detection of intra- and extra-luminal
tracheobronchial lesions. The use of multidetector CT
(MDCT) provides greater speed of image acquisition,
improved resolution and better contrast enhancement.84
The addition of multiplanar and three-dimensional recon-
struction can provide virtual images that precisely delin-
eate local and diffuse lesions and demonstrate the degree
of airways involvement. Evaluation of the longitudinal
extent of abnormalities, tracheal wall thickness, and extra-
luminal pathologies is also possible with this technique. The
use of dynamic CT can be helpful for the diagnosis of tra-
cheomalacia. Dynamic CT provides imaging of the entire
central airways in a few seconds and has a comparable
accuracy to that of bronchoscopy for diagnosing TM85 and
greater sensitivity compared to end-expiratory CT.86
Virtual bronchoscopy using three-dimensional recon-
struction from helical computed tomography images is
another novel CT-based imaging technique that offers a
noninvasive technique for visualization of the tracheo-
bronchial tree (Fig. 1, panel B). This modality provides
accurate assessment of fixed intraluminal lesions. However,
it does not replace the need for actual bronchoscopy.
Magnetic resonance imaging (MRI)
MRI is used mainly for the evaluation of the larynx and
trachea. The major advantage of MRI over CT is that it
provides excellent visualization of the larynx and entire
length of the trachea in coronal, transverse, and sagittal
plans without the need for contrast.87
Bronchoscopic evaluation
Bronchoscopy is very useful in the evaluation of tracheal
disorders. It can precisely determine the extent of the
lesion. Moreover, lesions can be biopsied for accurate
pathologic diagnosis. Another advantage of bronchoscopy is
to treat obstruction, if present, in order to provide an
airway adequate for further studies or therapeutic in-
terventions such as resection, stenting or irradiation. Rigid
bronchoscopy can provide a magnified image and accu-
rately delineate the extent of lesions. It can be used to
control bleeding and for removal of foreign bodies.
Different interventional bronchoscopic techniques can also
be applied through bronchoscopy such as electrocautery
and laser therapy (Fig. 2, panel A and B).
Figure 2 Panel A: post-traumatic tracheal stenosis, panel B:
post-traumatic tracheal stenosis, after stent placement.
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Spirometry is an essential test for the evaluation of causes
of shortness of breath. Maximum forced expiratory and
inspiratory maneuvers are done, and flow and volume are
simultaneous measured and depicted as the flow volume
loop (Fig. 3, panel A). Thus, abnormal airflow pattern can
give clues to the diagnosis of upper airway obstruction and
prompt further evaluation. However, a normal spirometry
should not preclude upper airway disorder from the dif-
ferential diagnosis.88 Since evidence of expiratory airflow
obstruction is usually caused by asthma or COPD, the less
common conditions of the upper airways often are not
considered in the differential diagnosis. The diagnosis may
be further delayed because upper airway obstruction must
be quite advanced before symptoms occur and lung func-
tion testing becomes abnormal. Studies suggest that an
upper airway obstruction must narrow the lumen of the
airway to less than 8 mm in diameter to produce abnor-
malities on the flow-volume loop.89,90 When an artificial
obstruction is imposed, the 1 s forced expiratory volume
(FEV1), remains above 90 percent of control until the orifice
is reduced to 6 mm. Peak expiratory flow may be affectedwith less obstruction. Although spirometry may not be a
sensitive way to detect upper airway abnormalities, certain
patterns suggest the diagnosis and should prompt further
investigation, especially if careful efforts were taken to
assure maximum effort during the testing.
Typical patterns of the flow-volume loop may be seen,
depending on whether the obstruction to flow is “fixed” or
“variable” and whether the site of the obstruction is above
or below the thoracic outlet or suprasternal notch. Fixed
obstructions of the upper airway are those whose cross-
sectional area does not change in response to transmural
pressure differences during inspiration or expiration. A
fixed obstruction may occur in either the intrathoracic or
extrathoracic airways. A variable obstruction is one that
responds to transmural pressure changes, eliciting varying
degrees of obstruction during the respiratory cycle. The
configuration of the flow volume curve may give clues to
the presence and site of obstruction.
Upper-airway obstruction should be suspected when a
plateau is seen suggesting a fixed point of obstruction.
Oscillations in the inspiratory or expiratory curves have also
been described, probably representing a mechanical
instability of the airway wall. A plateau of forced inspira-
tory flow alone suggests an extrathoracic upper airway
obstruction. (Fig. 3, panel B). With extrathoracic upper
airway obstruction, flow is limited only during inspiration.
Intraluminal pressure is subatmospheric during inspiration
for both the extrathoracic and intrathoracic trachea.
However, the transmural pressure of the extrathoracic
trachea is negative during inspiration whereas that of the
intrathoracic trachea is positive because the pressure sur-
rounding the extrathoracic trachea is atmospheric and the
pressure surrounding the intrathoracic trachea is subat-
mospheric. Thus the extrathoracic trachea will then be
more prone to collapse during inspiration and an extra-
thoracic upper airway lesion would cause airflow limitation
during inspiration. The opposite would be true for expira-
tion. Poor effort may result in abnormal inspiratory curve
and thus, a single inspiratory curve limitation should be
confirmed by looking at all the flow-volume loops.91
A plateau in the forced expiratory curve alone is seen
with a central obstruction in the intrathoracic airway as the
airways are influenced by the surrounding positive pleural
pressure during exhalation (Fig. 3, panel C). A pattern that
shows similar flow in both forced inspiratory and expiratory
flows suggests a fixed upper airway obstruction that may be
located in the extra or intrathoracic airway (Fig. 3, panel D).
Physiologic evaluation by spirometry and flow-volume
loop can be a simple and noninvasive method to assess for
improvement in upper airway obstruction following
intervention.
Management
Management of acute upper airway obstruction
The primary goal in management patients with upper
airway obstruction is maintain adequate oxygenation and
ventilation. General therapeutic measures for acute
obstruction may include elevation of the head of bed,
administration of humidified oxygen, inhaled racemic
Figure 3 Flow-volume loop. Normal pattern (panel A), variable extrathoracic obstruction (panel B), variable intrathoracic
obstruction (panel C), fixed upper airway obstruction (panel D).
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eoxygen gas mixture (Heliox) is a low-density gas,
commonly delivered as 80% helium/20% oxygen, that can be
used in management of reversible upper airway obstruc-
tion. This gas mixture has a low density because the helium
is replacing nitrogen. This results in conversion of the
predominantly turbulent flow at the site of obstruction to a
more laminar pattern. Laminar flow requires less pressure
gradient than turbulent flow to achieve the same flow rate,
thus it reduces the work of breathing. Oxygen can be
titrated to raise the FiO2. However, the benefit of the
mixture is lost as the FiO2 of the heliox mixture increases.
Maintaining airway adequate for oxygenation and
ventilation can be challenging in patients with upper airway
disease since they may deteriorate quickly. The most
experienced physician available should try to secure airway
in those patients. A variety of noninvasive and invasive
tools are available as alternatives to standard intubation.
Invasive methods include percutaneous needle cricothyr-
otomy, tracheostomy, fiberoptic endotracheal intubation,
and use of a rigid ventilating bronchoscope.
Management of chronic upper airway disorders
Therapies applied for chronic upper airway disorders
vary according to the underlying pathology, severity ofsymptoms, nature of the disease (ie. fixed stenosis resulting
in obstruction or dynamic with variable airway collaps-
ibility), duration of expected survival, and ultimate goals of
care.
Benign asymptomatic lesions generally do not require
specific therapies. Symptomatic patients may require
bronchial hygiene measures (to optimize secretion clear-
ance), and bronchodilators. In addition, immunosuppres-
sant therapy is required in patients with systemic diseases
(eg. relapsing polychondritis, sarcoidosis) affecting upper
airways.
Stenotic lesions can be treated by various surgical in-
terventions (eg. surgical excision, tracheostomy) depending
on the underlying etiology. In addition, a variety of less
invasive techniques can be applied through the broncho-
scope such as bronchoscopic dilatation, intralesional cor-
ticosteroids injection, laser therapy, photodynamic
therapy, cryotherapy, external beam radiation and
brachytherapy. Airway stents are used primarily as a palli-
ative measure of airway obstruction. Attention should be
paid to the rare but potentially fatal negative-pressure
pulmonary edema that may develop after relieving the
obstruction.
Patients with dynamic central airway collapsibility (ie.
tracheomalacia and EDAC) can be managed by continuous
positive airway pressure (CPAP) device to reduce expiratory
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used in selected patients.92 Membranous wall tracheoplasty
implies plication of the membranous wall to a mesh to
restore the normal airway configuration.
Advances in the management of tracheal
obstruction
Several types of stents are currently available and are
highly effective in alleviating symptoms of tracheal
obstruction. The most commonly used stents are silicone
stents, metal stents, and stents that combine a silicone or
synthetic coating with metal mesh (ie. hybrid stents).93
Metallic stents may be difficult to remove and may frag-
ment or penetrate into adjacent structures, although
newer models have avoided these complications. Self-
expanding metal stents are usually made of nitinol, which
has a high elasticity similar to cartilage. These stents can
be ‘covered’ with a plastic membrane to prevent tumor
growth inside the lumen. Silicon stents are inexpensive and
can be easily removed or exchanged if needed. However,
migration and adherence of secretions are the major dis-
advantages.94 More recently, a novel bioabsorbable drug-
eluting stents have been introduced with promising re-
sults. These stents allow sustained drug elution to minimize
or delay tracheal restenosis.
Patients who require surgical repair or resection of long
tracheal segment (more than one-half of the tracheal
length) usually need a repair tissue. Since the 1950’s,
different materials have been used for tracheal recon-
struction, including foreign materials, nonviable tissues,
autogenous tissues and tissue engineering.
Moreover, a new field of tracheal reconstructive surgery
has emerged in the last few years focusing on tracheal
replacement using tissue-engineering techniques. The first
tissue-engineered tracheal reconstruction was performed
in 2008, using a decellularized cadaveric tracheal segment
and the recipient’s own stem cells.95 In 2011, the first stem
cell-based bioartificial tracheal replacement surgery was
performed successfully.96 However, long-term outcomes of
these methods are yet to be determined.
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